ADMA Biologics (ADMA) to Release Earnings on Wednesday

ADMA Biologics (NASDAQ:ADMA) is expected to be announcing its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.15 per share and revenue of $112.80 million for the quarter.

ADMA Biologics Stock Down 1.5 %

Shares of NASDAQ ADMA opened at $15.84 on Monday. The firm has a market cap of $3.74 billion, a P/E ratio of 56.57 and a beta of 0.75. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics has a 1 year low of $5.08 and a 1 year high of $23.64. The firm’s 50 day moving average price is $16.97 and its 200 day moving average price is $18.00.

Analysts Set New Price Targets

Several research firms have recently issued reports on ADMA. HC Wainwright raised their price objective on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Raymond James raised their price target on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.